Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.24), $0.24 better than the analyst estimate of ($0.48). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE